Overview

Grifols is a global healthcare company that since its founding in Barcelona in 1909 has enhanced the health and well-being of people around the world. Our four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services in more than 100 countries. As pioneers in the field of plasma science, we are one of the largest plasma companies, with a growing network of donation centers worldwide. We develop this plasma into essential medicines used to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, we also offer a comprehensive portfolio of solutions designed to enhance safety from donation through transfusion. We continue to advance our legacy of innovation by supplying tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Grifols, S.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of plasma derivatives. Grifols S.A. develops, manufactures, and markets plasma derivatives, IV Therapy, enteral nutrition, diagnostic systems, and medical materials. Grifols, S.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of plasma derivatives, IV therapy, enteral nutrition, diagnostic systems, and medical materials worldwide. The company operates in three segments: Bioscience, Hospital, and Diagnostic. The Bioscience segment engages in the research, development, production, and commercialization of plasma derivates. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing diagnostics products for laboratory analysis, including products for hospital blood banks and transfusion centers. Its products and services include a line of blood collection and storage bags; a line of products to determine the hemostatic balance of a patient, including reagents, instruments, and software; Triturus analyzer for automating ELISA tests, as well as associated reagent panels; DianaGel and DG Gel cards for blood grouping and instruments for automated blood typing: the Diana processor, Twin Reader, and the WADiana analyzer; and a virus inactivation service for plasma transfused in the hospital. The Hospital segment provides a range of non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy, and for other therapeutic uses. It offers parenteral nutrition products, including the lipid emulsion Soyacal; diets, supplements, and disposable material for enteral nutrition; and a line of medication delivery tools. This segment also produces inventory management software for hospital pharmacies, profile systems software, laboratory analysis management software, and blood bank software; and distributes and installs automatic dispensing systems. The company was founded in 1940 and is based in Barcelona, Spain. Grifols is a group of companies, which serves healthcare professionals and patients in over 90 countries around the world. We research, develop, manufacture and market plasma derivatives, IV therapy, enteral nutrition, diagnostic systems and medical materials. For more than 75 years, Grifols has worked to improve the health and well-being of people around the world. We are a global healthcare company that produces essential plasma medicines for patients and provides hospitals, pharmacies, and healthcare professionals with the tools, information, and services they need to help them deliver expert medical care.Our three divisions—Bioscience, Diagnostic, and Hospital—develop, produce, and market innovative products and services available in more than 100 countries. Headquartered in Barcelona, Grifols has nearly 17,000 employees in 30 countries. With a network of approximately 180 donation centers in the U.S., we are the world leader in plasma collection and a leading producer of plasma medicines used to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, we offer a comprehensive portfolio of products designed to support safety from donation through transfusion. GRIFOLS INTERNATIONAL SA is located in PARETS DEL VALLES, Spain and is part of the Warehousing & Storage Industry. GRIFOLS INTERNATIONAL SA has 239 employees at this location and generates $509.92 million in sales (USD). There are 409 companies in the GRIFOLS INTERNATIONAL SA corporate family. GRIFOLS INTERNATIONAL SA is located in PARETS DEL VALLES, Spain and is part of the Warehousing & Storage Industry. GRIFOLS INTERNATIONAL SA has 239 employees at this location and generates $509.92 million in sales (USD). (Employees figure is estimated). There are 409 companies in the GRIFOLS INTERNATIONAL SA corporate family. Grifols produces plasma derivatives, or plasma proteins for therapeutic use, which are sold to hospitals, doctors, and other health care professionals around the world. Its Bioscience division operates plasma collection centers and processing facilities, as well as manufacturing, marketing, and distributing therapies. The Diagnostic division manufactures products that ensure blood transfusions are safe, test for blood clotting disorders or immune disorders. Grifols' Hospital division develops pharmaceutical products and medical devices used in hospital pharmacies. Grifols is present in approximately 100 countries with three-quarters of its sales coming from international markets. Try D&B Hoovers Free Grifols produces plasma derivatives, or plasma proteins for therapeutic use, which are sold to hospitals, doctors, and other health care professionals around the world. Its Bioscience division operates plasma collection centers and processing facilities, as well as manufacturing, marketing, and distributing therapies. The Diagnostic division manufactures products that ensure blood transfusions are safe, test for blood clotting disorders or immune disorders. Grifols' Hospital division develops pharmaceutical products and medical devices used in hospital pharmacies. Grifols is present in approximately 100 countries with three-quarters of its sales coming from international markets.

Reviews